• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Quantifying the Population-Level Effect of the COVID-19 Mass Vaccination Campaign in Israel: A Modeling Study

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2022 Feb 18;9(5):ofac087.
doi: 10.1093/ofid/ofac087. eCollection 2022 May.
Quantifying the Population-Level Effect of the COVID-19 Mass Vaccination Campaign in Israel: A Modeling Study


Ido Somekh[SUP] 1 2 [/SUP], Wasiur R KhudaBukhsh[SUP] 3 [/SUP], Elisabeth Dowling Root[SUP] 4 [/SUP], Lital Keinan Boker[SUP] 5 6 [/SUP], Grzegorz Rempala[SUP] 7 [/SUP], Eric A F Simões[SUP] 8 [/SUP], Eli Somekh[SUP] 2 9 [/SUP]



Affiliations

Abstract

Background: Estimating real-world vaccine effectiveness is challenging as a variety of population factors can impact vaccine effectiveness. We aimed to assess the population-level reduction in cumulative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases, hospitalizations, and mortality due to the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccination campaign in Israel during January-February 2021.
Methods: A susceptible-infected-recovered/removed (SIR) model and a Dynamic Survival Analysis (DSA) statistical approach were used. Daily counts of individuals who tested positive and of vaccine doses administered, obtained from the Israeli Ministry of Health, were used to calibrate the model. The model was parameterized using values derived from a previous phase of the pandemic during which similar lockdown and other preventive measures were implemented in order to take into account the effect of these prevention measures on COVID-19 spread.
Results: Our model predicted for the total population a reduction of 648 585 SARS-CoV-2 cases (75% confidence interval [CI], 25 877-1 396 963) during the first 2 months of the vaccination campaign. The number of averted hospitalizations for moderate to severe conditions was 16 101 (75% CI, 2010-33 035), and reduction of death was estimated at 5123 (75% CI, 388-10 815) fatalities. Among children aged 0-19 years, we estimated a reduction of 163 436 (75% CI, 0-433 233) SARS-CoV-2 cases, which we consider to be an indirect effect of the vaccine.
Conclusions: Our results suggest that the rapid vaccination campaign prevented hundreds of thousands of new cases as well as thousands of hospitalizations and fatalities and has probably averted a major health care crisis.

Keywords: COVID-19; effect; modeling; real-life; vaccination.
 
Back
Top Bottom